Biliary Tract Carcinoma Clinical Trial
Official title:
A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Participants With Unresectable Advanced Biliary Tract Carcinoma (BTC)
This is an open label, multi-center, phaseâ…¡study to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).
Biliary Tract Carcinoma (BTC) has an insidious onset, invasiveness, high malignancy, and no specific symptoms in the early stage, and most of them are in the middle and advanced stages at the time of diagnosis and have lost the chance of surgery. For patients with advanced BTC, systemic therapy is currently the main choice, and gemcitabine/cisplatin (GP) is currently the "gold standard" for first-line treatment of advanced BTC, but the efficacy is still unsatisfactory, and more and more clinical practice has found that GP-based combination therapy may have better efficacy. Previous studies have shown that chemotherapy can improve the immunotherapy microenvironment and may have a synergistic anti-tumor effect in combination with immunotherapy. This study is to explore the efficacy and safety of GP in combination with anti-PD1 antibody (Tislelizumab) and anti-TIGIT antibody (Ociperlimab) as first-line treatment in participants with unresectable advanced BTC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04003896 -
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04003636 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
|
Phase 3 | |
| Not yet recruiting |
NCT05064852 -
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
|
||
| Recruiting |
NCT05668884 -
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05123482 -
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
| Recruiting |
NCT06048133 -
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
|
Phase 2 | |
| Recruiting |
NCT05845554 -
Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
|
||
| Completed |
NCT00490399 -
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
|
Phase 2 | |
| Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
| Withdrawn |
NCT02105350 -
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
|
Phase 1 | |
| Recruiting |
NCT06047990 -
Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction
|
N/A | |
| Active, not recruiting |
NCT04924062 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
|
Phase 3 | |
| Terminated |
NCT04178460 -
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
|
Phase 1 | |
| Completed |
NCT03027284 -
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06199882 -
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06168292 -
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
|
N/A | |
| Recruiting |
NCT04979663 -
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04984980 -
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05822453 -
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
|
Phase 2 |